General Health
Dendritic Cell Immunotherapy for HIV-1: A Phase IIB Trial
Reference: Jacobson, J. M., Routy, J.-P., Welles, S., DeBenedette, M., Tcherepanova, I., Angel, J. B., Asmuth, D. M., Stein, D. K., Baril, J.-G., McKellar, M., Margolis, D. M., Trottier, B., Wood, K., & Nicolette, C. (2016). Dendritic cell immunotherapy for HIV-1 infection using autologous HIV-1 RNA: A randomized, double-blind, placebo-controlled clinical trial. Journal of Acquired
Immunization of HIV-1-Infected Persons with Dendritic Cells
Reference: Gandhi, R. T., Kwon, D. S., Macklin, E. A., Shopis, J. R., McLean, A. P., McBrine, N., Flynn, T., Peter, L., Sbrolla, A., Kaufmann, D. E., Porichis, F., Walker, B. D., Bhardwaj, N., Barouch, D. H., & Kavanagh, D. G. (2016). Immunization of HIV-1-Infected Persons With Autologous Dendritic Cells Transfected With mRNA Encoding HIV-1
Immunologic Activity and Safety of Autologous HIV RNA–Electroporated Dendritic Cells in HIV-1 Infected Patients
Reference: Routy, J.-P., Boulassel, M.-R., Yassine-Diab, B., Nicolette, C., Healey, D., Jain, R., Landry, C., Yegorov, O., Tcherepanov, I., Monesmith, T., Finke, L., & Sékaly, R.-P. (2010). Immunologic activity and safety of autologous HIV RNA–electroporated dendritic cells in HIV-1 infected patients receiving antiretroviral therapy. Clinical Immunology, 134(2), 140. https://doi.org/10.1016/j.clim.2009.09.009 Summary: This pilot study assessed the